Drug Approval | January 14, 2022
WHO recommends two new drugs for COVID-19
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
Hitz shall assume new role from January 17th, 2022
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
He has over 22 years of experience in pharmaceutical sales & business development
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Subscribe To Our Newsletter & Stay Updated
